ES2138086T3 - Constructo de peptido sintetico compuesto que provoca anticuerpos neutralizantes y linfocitos t citotoxicos contra hiv. - Google Patents

Constructo de peptido sintetico compuesto que provoca anticuerpos neutralizantes y linfocitos t citotoxicos contra hiv.

Info

Publication number
ES2138086T3
ES2138086T3 ES94919119T ES94919119T ES2138086T3 ES 2138086 T3 ES2138086 T3 ES 2138086T3 ES 94919119 T ES94919119 T ES 94919119T ES 94919119 T ES94919119 T ES 94919119T ES 2138086 T3 ES2138086 T3 ES 2138086T3
Authority
ES
Spain
Prior art keywords
hiv
rat
peptides
nhc
branches
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919119T
Other languages
English (en)
Inventor
Jay A Berzofsky
Jeffrey D Ahlers
C David Pendleton
Peter Nara
Mutsunori Shirai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2138086T3 publication Critical patent/ES2138086T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CONSTRUCCIONES PEPTIDAS QUE INCLUYEN PEPTIDOS AYUDANTES DEL MULTIDETERMINANTE T DE LA GLICOPROTEINA ENVUELTA DE VIH PREVIAMENTE IDENTIFICADA PARA INDUCIR RESPUESTAS PROLIFERATIVAS EN CUATRO HAPLOTIPOS DIFERENTES DE RATAS Y RESPUESTAS IL-2 EN EL 52-73% DE LOS VIH POSITIVOS; PACIENTES CON GRIPE (PEPTIDOS AGLOMERANTES) FUERON SINTETIZADOS COLINEALMENTE CON EL PEPTIDO 18 DEL ANILLO V3 DE VIH-1 GP 160, CORRESPONDIENTE AL DETERMINANTE NEUTRALIZADOR PRINCIPAL DE VIH-IIIB Y QUE TAMBIEN DEMUESTRAN CONTENER UN EPITOPO CTL. LA AYUDA ANALOGA PARA EL ANTICUERPO DE PEPTIDO 18 FUE INCITADA SIGUIENDO UNA SOLA INMUNIZACION EN TODOS LAS RAMAS DE RATAS QUE HABIAN RESPONDIDO PREVIAMENTE AL EPITOPO DE CELULA T INCLUIDO POR LOS PEPTIDOS. EN DOS RAMAS DE RATAS, EL NIVEL DE ANTICUERPO NEUTRALIZADOR CONSEGUIDO FUE COMPARABLE A LOS NIVELES ADECUADOS PARA LA PROTECCION DE RETOS VIRALES HOMOLOGOS EN CHIMPACES. DESPUES DE UN SOLO CHOQUE, SE CONSIGUIERON ANTICUERPOS MUCHO MAS ELEVADOS QUE RONDARON EL 90% DE NEUTRALIZACION EN EL INTERVALO DE 1:1000 A 1:16000. CELULAS DE BAZO DE LAS RATAS DE 3 HAPLOTIPOS NHC DIFERENCIADOS QUE COMPARTEN EL D{SUP,D} DE CLASE I DE LA MOLECULA NHC PERO CON DIFERENTES MOLECULAS DE CLASE II, INMUNIZADAS CON LOS PEPTIDOS DEL COMPUESTO, EXHIBIERON UNA ACTIVIDAD CTL GP 160-ESPECIFICA REFORZADA.
ES94919119T 1993-05-14 1994-05-13 Constructo de peptido sintetico compuesto que provoca anticuerpos neutralizantes y linfocitos t citotoxicos contra hiv. Expired - Lifetime ES2138086T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/060,988 US6294322B1 (en) 1988-01-26 1993-05-14 Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1

Publications (1)

Publication Number Publication Date
ES2138086T3 true ES2138086T3 (es) 2000-01-01

Family

ID=22032969

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919119T Expired - Lifetime ES2138086T3 (es) 1993-05-14 1994-05-13 Constructo de peptido sintetico compuesto que provoca anticuerpos neutralizantes y linfocitos t citotoxicos contra hiv.

Country Status (11)

Country Link
US (4) US6294322B1 (es)
EP (1) EP0701572B1 (es)
JP (2) JP3802049B2 (es)
AT (1) ATE183200T1 (es)
AU (1) AU688333B2 (es)
CA (1) CA2162880C (es)
DE (1) DE69420034T2 (es)
DK (1) DK0701572T3 (es)
ES (1) ES2138086T3 (es)
GR (1) GR3031790T3 (es)
WO (1) WO1994026785A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
NZ290089A (en) * 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
US6749856B1 (en) * 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
CA2303410A1 (en) * 1997-09-11 1999-03-18 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Mucosal cytotoxic t lymphocyte responses
JP2002524554A (ja) * 1998-09-15 2002-08-06 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 除草剤として有用なピリジンケトン
US7611721B1 (en) 1999-05-13 2009-11-03 Wyeth Holdings Corporation Adjuvant combination formulations
FR2799465B1 (fr) * 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
IL150961A0 (en) 2000-02-04 2003-02-12 Univ Duke Human immunodeficiency virus vaccine
EP1280551B1 (en) * 2000-04-27 2007-01-10 Sanofi Pasteur Limited Vaccines against hiv infection
WO2002055100A2 (en) 2000-10-20 2002-07-18 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
PE20020530A1 (es) * 2000-11-10 2002-06-18 Wyeth Corp Formulaciones de combinacion adyuvante
AU2002350047A1 (en) * 2001-10-29 2003-05-12 Genzyme Corporation Therapeutic anti-hiv (vpr) compounds
WO2003051285A2 (en) * 2001-10-29 2003-06-26 Genzyme Corporation Therapeutic anti-hiv (iv9) compounds
WO2005005465A2 (en) * 2003-07-08 2005-01-20 Board Of Regents, University Of Texas System Methods and compositions to enhance immune responses via recall antigens
US20090214583A1 (en) * 2004-04-30 2009-08-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Epitope-enhancement of a human cd4 hiv epitope
US20080038284A1 (en) * 2004-11-08 2008-02-14 Haynes Barton F Human Immunodeficiency Virus Vaccine
EP2013227A4 (en) * 2006-05-09 2010-07-28 Jackson H M Found Military Med HIV-1 immunostained compositions
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US4817966A (en) * 1988-02-03 1989-04-04 Garlock Inc. Rotary shaft bearing isolator seal
EP0362909A3 (en) 1988-08-26 1990-11-14 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv-antibodies
EP0448095A1 (en) 1990-03-21 1991-09-25 Wolf, Hans Joachim, Prof. Dr. Subregion of the retroviral ENV protein, DNA sequences encoding it and compositions for the diagnosis, prevention or therapy of retrovirus infections
CA2114849C (en) 1991-08-29 2007-04-24 Jay A. Berzofsky Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects

Also Published As

Publication number Publication date
AU688333B2 (en) 1998-03-12
US6214347B1 (en) 2001-04-10
JP2006056893A (ja) 2006-03-02
DE69420034D1 (de) 1999-09-16
EP0701572A1 (en) 1996-03-20
EP0701572B1 (en) 1999-08-11
ATE183200T1 (de) 1999-08-15
US5932218A (en) 1999-08-03
JPH09500614A (ja) 1997-01-21
DK0701572T3 (da) 2000-03-13
DE69420034T2 (de) 2000-03-02
WO1994026785A1 (en) 1994-11-24
JP3802049B2 (ja) 2006-07-26
US6294322B1 (en) 2001-09-25
US7094405B1 (en) 2006-08-22
GR3031790T3 (en) 2000-02-29
AU7017394A (en) 1994-12-12
CA2162880C (en) 2003-02-11
CA2162880A1 (en) 1994-11-24

Similar Documents

Publication Publication Date Title
Chanh et al. Synthetic peptides homologous to HIV transmembrane glycoprotein suppress normal human lymphocyte blastogenic response
DK0701572T3 (da) Sammensat syntetisk peptidkonstruktion, der fremkalder neutraliserende antistoffer og cytotoksiske T-lymfocytter mod HIV
Takahashi et al. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant
Leonard et al. Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection.
Gahéry-Ségard et al. Multiepitopic B-and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
MX9302964A (es) Vacunas de clostridium perfringens.
AU629180B2 (en) Antibody heteroconjugates for the killing of hiv infected cells
ES2139017T3 (es) Compuestos que inhiben la replicacion del vih.
FI903866A0 (fi) Terapeutiskt aktiva albuminderivat.
BRPI9912175A (pt) peptídios de antígeno cd4-cdr2, composição farmacêutica compreendendo os mesmos bem como uso da mesma
ES2112838T3 (es) Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
ES2124922T3 (es) Peptidos derivados de un retrovirus del grupo hiv y su uso.
ID30497A (id) Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
PE20240491A1 (es) Peptidos y metodos para el tratamiento de esclerosis multiple
Kinter et al. Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
ES2118058T3 (es) Factor de crecimiento de las celulas t.
Nygren et al. 95-and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor.
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
BR0114046A (pt) Peptìdeos reguladores e auxiliares de hiv, antìgenos, composições de vacinas, kit de imunoensaio e um método para detectar anticorpos induzidos por hiv
ITRM920350A1 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
ES2059577T3 (es) Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion.
US5981278A (en) Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 701572

Country of ref document: ES